Bone marrow mononuclear cell pre-seeding of polycarbonate bisurea-based tissue-engineered heart valves has detrimental effects on long-term performance and in situ remodeling and, therefore, should be avoided.
PC-BU TEHV
T ranscatheter heart valve replacement (TVR) approaches were initially introduced to treat patients considered ineligible or at too high risk for surgical valve replacement (1) . Currently, TVR techniques are being extended successfully to cohorts of lower risk patients (1) (2) (3) . Valve prostheses compatible with TVR techniques are, however, still based on glutaraldehyde-fixed xenogeneic materials prone to calcification and degeneration, causing a high incidence of re-operations (4) . Thus, novel TVR-compatible prostheses that remain functional throughout the patient's life are needed.
We recently proposed the use of bioresorbable polymers for the development of "off-the-shelf" available tissue-engineered heart valves (TEHVs) with in situ remodeling potential (5) . In situ tissue engineering involves implanting a cell-free scaffold that should promote host cell adhesion and infiltration, and induce tissue formation by gradual substitution of the bioresorbable prosthesis by a living, native-like tissue (6) . We previously showed that TEHVs based on the bioresorbable polymer bisurea-modified polycarbonate (PC-BU) retained functionality for up to 1 year in sheep when surgically implanted in a (5) . The implanted valves exhibited gradual host cell repopulation while the polymer was partially replaced by newly synthetized extracellular matrix (ECM). This approach is suited for clinical translation due to the off-the-shelf availability of the valves, low production cost, scalability, and reduced logistical complexity. Recently, a pulmonary valve conduit based on this concept showed acceptable preclinical safety and performance as well as cell infiltration and neo-tissue formation, with partial degradation of the polymer over the 12 months' follow-up (7) ; this conduit has advanced into a clinical pilot trial in children (NCT02700100, NCT03022708, and NCT03405636).
The in situ approach strongly relies, however, on the regenerative cascade induced by the inflammatory response that occurs after valve implantation (6, 8) . To be able to control the host's response, bone marrow mononuclear cell (BMMNC) pre-seeding has been validated on bioresorbable vascular grafts (BVGs) in both preclinical (9, 10) and clinical (11, 12) settings.
BVGs pre-seeded with BMMNCs exhibited accelerated cellular infiltration and better remodeling toward native-like tissue architecture in a cytokine-mediated process in various animal models (9, 10, 13) . The cytokine monocyte chemoattractant protein-1 (MCP-1), which can be secreted by BMMNCs, has been shown to influence macrophage infiltration and favor remodeling toward a well-organized vascular tissue (10, 13, 14) .
Based on these findings, we hypothesized that preseeding PC-BU transcatheter TEHVs with BMMNCs would lead to a favorable remodeling response similar to the one observed in vascular grafts in small (10, 13, 15) and large (9, 16) animal models. In addition, we previously showed that pre-seeding of BMMNC onto biodegradable polymeric scaffolds (based on polyglycolic acid) is feasible and compatible with transcatheter pulmonary (17) and aortic (18) (19) (20) valve replacement techniques.
To test this hypothesis, transcatheter TEHVs based on the supramolecular polymer PC-BU were seeded with BMMNCs within a one-step intervention (17) (18) (19) (20) and implanted as pulmonary TVR in a translational sheep model for chronic in vivo evaluation. In addition to assessing the overall feasibility and in vivo performance of such valves for up to 6 months, nonseeded TEHVs from a previous report (5) Table 2 ).
The following time points were considered: 4 h (n ¼ 2) to prove principal safety and feasibility, and 4 weeks (n ¼ 2) and 24 weeks (n ¼ 4) to assess valve functionality and remodeling potential. Nonseeded TEHVs (n ¼ 6; TEHV_1 to TEHV_6), which were from a previous report (5) and that were produced under the same conditions, served as a control group for this study with identical time points: 4 h (n ¼ 1), 4 weeks (n ¼ 2), and 24 weeks (n ¼ 3).
In vivo and ex vivo analyses were performed for all pre-seeded and control explants to assess the differences in valve remodeling via quantitative and semiquantitative analyses (as described later). Transapical transcatheter pulmonary valve replacement was performed as previously described (21) and detailed in Supplemental Materials 1.4. In short, following a right-sided thoracotomy, the right cardiac ventricle was exposed, the apex was punctured, and a guidewire inserted. After crimping a diameter of 28 mm to a diameter of 10 mm, the TEHV was loaded into a custom-made, pressure-based de- Figure 1F ). TEE-assessed mean and peak transvalvular gradient ranges were low (Supplemental Table 6 ). Two animals (BM-TEHV_6
and BM-TEHV_7) were euthanized pre-term after Figure 5B ). Differential leaflet remodeling was also observed in the gene expression profile of each single leaflet harvested from pre-seeded or nonseeded TEHVs (Figure 3 ) and in the leaflet thickness ( Figure 6 ) and length (Figure 7) . Generally, thickening (thickness value >1,000 mm) was observed in the lower wall and hinge areas of the leaflets, whereas minimal tissue deposition was observed toward the free edges. However, explant thickness measured in different leaflet regions proved to be significantly different among leaflets of the same valve ( Figure 6) . Effective neo-tissue leaflet length (Supplemental Figure 11C ) was compared with that of the visible scaffold for each leaflet of the valve.
Due to leaflet encapsulation by neointimal tissue, considerable leaflet shortening (>8%) was observed on both nonseeded and pre-seeded valves (Figure 7) .
Notably, valve BM-TEHV_6 showed leaflet shortening caused by folding of the leaflet tip toward the fibrosa side and fusion with the underlying tissue (Supplemental Figure 12 ). The current study tested the feasibility of influencing the initial host response by pre-seeding the PC-BU TEHVs with autologous BMMNCs in a one-step approach. The results were compared with nonseeded TEHVs from a previous report (5) , which served as the control group for the current study.
DISCUSSION
Other than valve functionality, we comparatively analyzed the remodeling of each valve leaflet by using both quantitative and qualitative assessments to further gain insight into the remodeling processes of these bioresorbable valves.
IMPACT OF BMMNC PRE-SEEDING ON TEHV
FUNCTIONALITY AND REMODELING. BMMNCs are an accessible cell source already used in clinical settings to pre-seed BVGs for the treatment of congenital single-ventricle anomalies (11, 12) . The safety of using such an autologous cell source in combination with BVGs in pediatric cardiovascular surgery has thus been established.
Next, pre-seeding of BMMNCs onto biodegradable polyglycolic acid (PGA)-based scaffolds proved to be feasible and compatible with transcatheter pulmonary valve replacement in non-human primates (17) and transcatheter aortic valve replacement in sheep (18) (19) (20) . In line with the current study, Weber et al. (17) reported adequate valve functionality with mild to moderate regurgitation and detected substantial cellular infiltration and tissue remodeling, whereas any macroscopic calcifications were absent after comparable to what was previously reported (17, 18, 20) , with similar marker expression for CD45, CD11b, CD31, CD34, and CD44 as reported by Emmert et al. (20) . However, the current study substantially differs from the aforementioned investigations (17, 18, 20) in terms of the following: 1) the valve ma- Interestingly, nonseeded PC-BU TEHVs did not present calcified nodules, even at later time points (5) .
This outcome suggests that the presence of calcific deposits observed here in the BM-TEHVs was induced by the pre-seeding (22) and not by the material itself, as observed in other studies using other supramolecular polymers (7) .
This hypothesis is also supported by the gene expression analysis, in which the genes involved in the activation of valve interstitial cells (TGF-b1 and IL-6), in calcification (B-GLAP and bone morphogenetic protein-2), and in matrix remodeling of regurgitant and stenotic valves (MMP-3 and MMP-9) (23) were more highly expressed in pre-seeded valves compared with the nonseeded TEHVs. We hypothesize that although the local release of MCP-1 proved to be beneficial for integration and remodeling of BVGs (10, 14) , it may lead to undesired outcomes in heart valve replacements because high levels of this cytokine were found in the calcified aortic valve sections (24) . The cellular mechanisms by which BMMNC preseeding seems to inversely influence the remodeling of vessels and valves remain to be elucidated. One distinguishing factor may be the difference in hemodynamic loading, as previous in vitro studies have shown that the chemotactic effects of both pre-seeded BM-derived mesenchymal stromal cells and MCP-1 on monocyte-derived macrophages depend on hemodynamic loading (25, 26) .
DIFFERENTIAL VALVE AND LEAFLET REMODELING.
Both the explanted pre-seeded and nonseeded TEHVs displayed substantial variability in the remodeling outcomes that were not only pre-seeding dependent but also valve and leaflet dependent. The current study provides, for the first time, an in-depth overview of the remodeling of each valve leaflet by using quantitative and semi-quantitative analyses.
Notably, signs of undesired leaflet remodeling (e.g., leaflet encapsulation and shortening, presence of aSMA-positive cells) were observed in both study groups.
Impact of valve positioning on tissue remodeling.
Native valves are subjected to leaflet-dependent hemodynamic loading (27, 28 Figure 1C) (5, 7) . Such heterogeneity may affect the safety of these supramolecular TEHVs, challenging their potential clinical translation (39) . We therefore suggest the need to further investigate and understand the in situ remodeling potential of these transcatheter supramolecular TEHVs by gaining indepth knowledge of the biological remodeling processes (e.g., by using in-silico and in-vitro models [40] , and by comprehensive sheep-specific histopathological analysis [41] ). In addition, ensuring valve antithrombogenicity is fundamental to prevent thrombotic and thromboembolic adverse events. In the current study, and similarly to what was previously reported for surgically implanted PC-BU TEHVs at 6 months' follow-up (5) , incomplete leaflet endothelialization was observed in the majority of the valve leaflets, with the presence of scaffold-exposed areas (particularly toward the leaflet-free edge). 
